Kazia director granted 100,000 stock options

Kazia Therapeutics director Steven R. S. Coffey reported a grant of 100,000 employee stock options over ADSs.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kazia Therapeutics director Steven R. S. Coffey reported a grant of 100,000 employee stock options over ADSs. The options carry an exercise price of $9.10 per ADS, were granted for no consideration, vest on January 8, 2027, and expire on January 8, 2029. Following this award, he holds 100,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Coffey Steven R. S.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	100,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 100,000 contracts (Direct)

Footnotes (1)

F1. Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Key Figures

Option grant size: 100,000 options over ADSs Exercise price: $9.10 per ADS Vesting date: January 8, 2027 +2 more

5 metrics

Option grant size 100,000 options over ADSs Board-approved award to director Steven R. S. Coffey

Exercise price $9.10 per ADS Exercise price reflecting Australian tax considerations

Vesting date January 8, 2027 Options vest on this date

Expiration date January 8, 2029 Options expire if not exercised by this date

Post-transaction derivative holdings 100,000 derivative securities Total options held directly after grant

Key Terms

Employee Stock Option (right to buy), ADSs, Remuneration Committee, employee share plan

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

ADSs financial

"Represents a board-approved award of 100,000 options over ADSs"

Remuneration Committee financial

"approved by the Remuneration Committee on January 8, 2026"

A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kazia Therapeutics (KZIA) disclose?

Kazia Therapeutics disclosed a board-approved grant of 100,000 employee stock options to director Steven R. S. Coffey. These options relate to ADSs and were issued as part of the company’s employee share plan.

What is the exercise price of the new KZIA stock options?

The granted options have an exercise price of $9.10 per ADS. The footnote notes that for Australian resident participants, this exercise price reflects Australian tax considerations under the issuer’s employee share plan.

When do Steven Coffey’s new Kazia options vest and expire?

The 100,000 options granted to Steven R. S. Coffey vest on January 8, 2027. According to the disclosure, these options expire on January 8, 2029 if they are not exercised before that date.

Did Steven Coffey pay anything for the newly granted KZIA options?

No cash consideration was paid for the options. The filing states that the 100,000 options over ADSs were granted for no consideration, reflecting a typical equity-based compensation award approved by the board’s Remuneration Committee.

How many derivative securities does Steven Coffey hold after this KZIA grant?

After this transaction, Steven R. S. Coffey holds 100,000 derivative securities directly. This amount matches the size of the new employee stock option award reported in the Form 4 transaction table.

Who approved the Kazia Therapeutics option grant to Steven Coffey?

The options were approved by the company’s Remuneration Committee on January 8, 2026. The footnote specifies this committee approval and describes the grant as a board-approved award under the issuer’s employee share plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/08/2026 - 04:59 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coffey Steven R. S.

(Last)

(First)

(Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY, NSW

2000

(City)

(State)

(Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$9.1	01/08/2026		A		100,000⁽¹⁾		⁽¹⁾	⁽¹⁾	ADSs	100,000	$0	100,000	D

Explanation of Responses:

1. Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

	/s/ Jeffrey Bonacorda - Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR